DRB18

DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity[1].

Product Specifications

CAS Number

[2863686-81-9]

UNSPSC

12352005

Target

GLUT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/drb18.html

Concentration

10mM

Purity

99.58

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=CC(NCC2=CC(O)=C(C)C=C2)=C(NCC3=CC=C(C)C(O)=C3)C=C1

Molecular Formula

C22H23ClN2O2

Molecular Weight

382.88

References & Citations

[1]Shriwas P, Roberts D, Li Y, et al. A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism. Cancer Metab. 2021;9 (1) :14. Published 2021 Mar 26.